Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

Novo Nordisk has more than enough of its Wegovy weight-loss pills to support an aggressive product launch, CEO Mike Doustdar ...

Wegovy-maker Novo Nordisk's CEO said on Monday a deal with the White House to slash prices on its popular weight‑loss drugs ...

The appointments come after the company’s controlling shareholder pushed for more changes to revive its success in the weight ...

Novo Nordisk's top shareholder forced through an overhaul of the Wegovy-maker's board at an extraordinary shareholder meeting ...

After [losing out to Pfizer]( ...

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

The boardroom shake-up, which erupted when Novo's board Chair Helge Lund and the independent members stepped down last month ...

Investing.com -- Novo Nordisk ’s CEO Mike Doustdar said Monday that the company’s agreement with the White House to reduce prices on its popular weight-loss drugs is designed to expand access through ...